An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease-Reference-Cited by-同舟云学术

An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease

Published:2009-12 Issue:3 Volume:36 Page:425-434
ISSN:0969-9961
Container-title:Neurobiology of Disease
language:en
Short-container-title:Neurobiology of Disease

Author:

Lord Anna,Gumucio Astrid,Englund Hillevi,Sehlin Dag,Sundquist Valentina Screpanti,Söderberg Linda,Möller Christer,Gellerfors Pär,Lannfelt Lars,Pettersson Frida Ekholm,Nilsson Lars N.G.

Publisher

Elsevier BV

Subject

Neurology

Reference50 articles.

1. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy;Bacskai;J. Neurosci.,2002

2. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology;Bard;Proc. Natl. Acad. Sci. U. S. A.,2003

3. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease;Bard;Nat. Med.,2000

4. Intraneuronal abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice;Billings;Neuron,2005

5. Alzheimer's disease;Blennow;Lancet,2006

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent updates on immunotherapy in neurodegenerative diseases;Brain Research;2024-12

2. Food and Drug Administration (FDA) Approvals of Biological Drugs in 2023;Biomedicines;2024-09-02

3. Disease modifying effects of the amyloid-beta protofibril-selective antibody mAb158 in aged Tg2576 transgenic mice;Molecular and Cellular Neuroscience;2024-09

4. Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains;Molecular and Cellular Neuroscience;2024-09

5. Population pharmacokinetics and exposure–response analyses of safety (ARIA‐E and isolated ARIA‐H) of lecanemab in subjects with early Alzheimer's disease;CPT: Pharmacometrics & Systems Pharmacology;2024-08-29